Toll Free: 1-888-928-9744

The Medicines Company - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The Medicines Company - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2014', provides an overview of the The Medicines Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of The Medicines Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of The Medicines Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of The Medicines Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the The Medicines Company's pipeline products

Reasons to buy

- Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of The Medicines Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the The Medicines Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of The Medicines Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of The Medicines Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of The Medicines Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
The Medicines Company Snapshot 5
The Medicines Company Overview 5
Key Information 5
Key Facts 5
The Medicines Company - Research and Development Overview 6
Key Therapeutic Areas 6
The Medicines Company - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
The Medicines Company - Pipeline Products Glance 14
The Medicines Company - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 15
The Medicines Company - Clinical Stage Pipeline Products 16
Phase I Products/Combination Treatment Modalities 16
The Medicines Company - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
The Medicines Company - Drug Profiles 18
cangrelor 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
oritavancin disphosphate 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
(biapenem + RPX-7009) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(RPX-2014 + RPX-7009) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MDCO-216 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Rec Fibrinogen Injectable Hemostat 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
tigecycline 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
The Medicines Company - Pipeline Analysis 28
The Medicines Company - Pipeline Products by Target 28
The Medicines Company - Pipeline Products by Route of Administration 29
The Medicines Company - Pipeline Products by Molecule Type 30
The Medicines Company - Pipeline Products by Mechanism of Action 31
The Medicines Company - Recent Pipeline Updates 32
The Medicines Company - Dormant Projects 38
The Medicines Company - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
clopidogrel bisulfate 39
MDCO-2010 39
The Medicines Company - Company Statement 40
The Medicines Company - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47
List of Tables
The Medicines Company, Key Information 5
The Medicines Company, Key Facts 5
The Medicines Company - Pipeline by Indication, 2014 8
The Medicines Company - Pipeline by Stage of Development, 2014 9
The Medicines Company - Monotherapy Products in Pipeline, 2014 10
The Medicines Company - Combination Treatment Modalities in Pipeline, 2014 11
The Medicines Company - Partnered Products in Pipeline, 2014 12
The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2014 13
The Medicines Company - Pre-Registration, 2014 14
The Medicines Company - Filing rejected/Withdrawn, 2014 15
The Medicines Company - Phase I, 2014 16
The Medicines Company - Preclinical, 2014 17
The Medicines Company - Pipeline by Target, 2014 28
The Medicines Company - Pipeline by Route of Administration, 2014 29
The Medicines Company - Pipeline by Molecule Type, 2014 30
The Medicines Company - Pipeline Products by Mechanism of Action, 2014 31
The Medicines Company - Recent Pipeline Updates, 2014 32
The Medicines Company - Dormant Developmental Projects,2014 38
The Medicines Company - Discontinued Pipeline Products, 2014 39
The Medicines Company, Other Locations 42
The Medicines Company, Subsidiaries 43 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify